Titolo/oggetto del contratto di sperimentazione
An open-label, randomized, phase 3 study of linvoseltamab (REGN5458; anti-BCMA x anti-CD3 bispecifiantibody) versus the combination of elotuzumab, pomalidomide, and dexamethasone (ePD), in patients witrelapsed/refractory multiple myeloma (LINKER-MM3)”